Secondary pulmonary hemosiderosis

Summary

Secondary pulmonary hemosiderosis (MONDO:0020553) is a disease. A subtype of interstitial lung disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	secondary pulmonary hemosiderosis
Mondo ID	MONDO:0020553
Orphanet	99930
ICD-11	878618614
SNOMED CT	716712004
UMLS	C4274326
MedGen	909854
GARD	0019713
Is cancer (heuristic)	no

Disease family

This is a subtype of interstitial lung disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › lung disorder › interstitial lung disease › secondary pulmonary hemosiderosis

Related subtypes (13): pulmonary fibrosis, bronchiolitis obliterans syndrome, pneumoconiosis, pulmonary fibrosis-hepatic hyperplasia-bone marrow hypoplasia syndrome, interstitial lung disease specific to childhood, isolated pulmonary capillaritis, interstitial lung disease specific to adulthood, drug or radiation exposure-related interstitial lung disease, hypersensitivity pneumonitis, inherited interstitial lung disease, radiation pneumonitis, bronchiolocentric pattern of interstitial pneumonia, idiopathic pulmonary fibrosis

Subtypes (1): Heiner syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.